These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 38393391)
21. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization. Nguyen VTC; Nguyen TH; Doan NNT; Pham TMQ; Nguyen GTH; Nguyen TD; Tran TTT; Vo DL; Phan TH; Jasmine TX; Nguyen VC; Nguyen HT; Nguyen TV; Nguyen THH; Huynh LAK; Tran TH; Dang QT; Doan TN; Tran AM; Nguyen VH; Nguyen VTA; Ho LMQ; Tran QD; Pham TTT; Ho TD; Nguyen BT; Nguyen TNV; Nguyen TD; Phu DTB; Phan BHH; Vo TL; Nai THT; Tran TT; Truong MH; Tran NC; Le TK; Tran THT; Duong ML; Bach HPT; Kim VV; Pham TA; Tran DH; Le TNA; Pham TVN; Le MT; Vo DH; Tran TMT; Nguyen MN; Van TTV; Nguyen AN; Tran TT; Tran VU; Le MP; Do TT; Phan TV; Nguyen HL; Nguyen DS; Cao VT; Do TT; Truong DK; Tang HS; Giang H; Nguyen HN; Phan MD; Tran LS Elife; 2023 Oct; 12():. PubMed ID: 37819044 [TBL] [Abstract][Full Text] [Related]
22. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy. Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552 [TBL] [Abstract][Full Text] [Related]
23. Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. Rusan M; Andersen RF; Jakobsen A; Steffensen KD Eur J Cancer; 2020 Jan; 125():121-129. PubMed ID: 31865042 [TBL] [Abstract][Full Text] [Related]
24. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma. Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920 [TBL] [Abstract][Full Text] [Related]
25. Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical hodgkin lymphoma treated with sintilimab. Shi Y; Su H; Song Y; Jiang W; Sun X; Qian W; Zhang W; Gao Y; Jin Z; Zhou J; Jin C; Zou L; Qiu L; Li W; Yang J; Hou M; Xiong Y; Zhou H; Du X; Wang X; Peng B EBioMedicine; 2020 Apr; 54():102731. PubMed ID: 32304999 [TBL] [Abstract][Full Text] [Related]
26. Early Circulating Tumour DNA Variations Predict Tumour Response in Melanoma Patients Treated with Immunotherapy. Keller L; Guibert N; Casanova A; Brayer S; Farella M; Delaunay M; Gilhodes J; Martin E; Balagué G; Favre G; Pradines A; Meyer N Acta Derm Venereol; 2019 Feb; 99(2):206-210. PubMed ID: 30393817 [TBL] [Abstract][Full Text] [Related]
27. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503 [TBL] [Abstract][Full Text] [Related]
29. Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer. Turner NC; Swift C; Jenkins B; Kilburn L; Coakley M; Beaney M; Fox L; Goddard K; Garcia-Murillas I; Proszek P; Hall P; Harper-Wynne C; Hickish T; Kernaghan S; Macpherson IR; Okines AFC; Palmieri C; Perry S; Randle K; Snowdon C; Stobart H; Wardley AM; Wheatley D; Waters S; Winter MC; Hubank M; Allen SD; Bliss JM; Ann Oncol; 2023 Feb; 34(2):200-211. PubMed ID: 36423745 [TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Borghaei H; Langer CJ; Paz-Ares L; Rodríguez-Abreu D; Halmos B; Garassino MC; Houghton B; Kurata T; Cheng Y; Lin J; Pietanza MC; Piperdi B; Gadgeel SM Cancer; 2020 Nov; 126(22):4867-4877. PubMed ID: 32914866 [TBL] [Abstract][Full Text] [Related]
31. Serial ultra-deep sequencing of circulating tumor DNA reveals the clonal evolution in non-small cell lung cancer patients treated with anti-PD1 immunotherapy. Li L; Wang Y; Shi W; Zhu M; Liu Z; Luo N; Zeng Y; He Y Cancer Med; 2019 Dec; 8(18):7669-7678. PubMed ID: 31692284 [TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994 [TBL] [Abstract][Full Text] [Related]
33. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Ma F; Guan Y; Yi Z; Chang L; Li Q; Chen S; Zhu W; Guan X; Li C; Qian H; Xia X; Yang L; Zhang J; Husain H; Liao Z; Futreal A; Huang J; Yi X; Xu B Int J Cancer; 2020 Mar; 146(5):1359-1368. PubMed ID: 31241775 [TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554 [TBL] [Abstract][Full Text] [Related]
35. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Kawachi H; Tamiya M; Tamiya A; Ishii S; Hirano K; Matsumoto H; Fukuda Y; Yokoyama T; Kominami R; Fujimoto D; Hosoya K; Suzuki H; Hirashima T; Kanazu M; Sawa N; Uchida J; Morita M; Makio T; Hara S; Kumagai T Invest New Drugs; 2020 Feb; 38(1):211-218. PubMed ID: 31784866 [TBL] [Abstract][Full Text] [Related]
36. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K; Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674 [TBL] [Abstract][Full Text] [Related]